A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study focuses on finding a safe and tolerable dose for a three-drug regimen that
combines venetoclax (Venclexta Ⓡ), CC-486 (also known as oral azacitidine) and obinutuzumab
(Gazyva Ⓡ) to treat cancer participants who have minimally pretreated follicular lymphoma and
have experienced disease progression despite trying previous cancer therapies. If a safe and
tolerable drug dose can be found in the first phase of the study, doctors leading the study
will launch a second phase of the study within an expansion cohort. Participants in this
expansion cohort will receive the dose established in the first phase of the study to
determine the efficacy of the regimen/ established dose. Participants in the expansion cohort
will also receive the same study drugs from the first phase of the study, but in a different
order/combination (first pairing the two oral drugs, CC-486 and venetoclax, then adding the
third drug, obinutuzumab to treatment). The end goal of this research is to establish a new
chemotherapy-sparing treatment option for patients with follicular lymphoma that is just as
effective (or better) than current standard of care options.